Drug General Information
Drug ID
D07GDN
Former ID
DCL000252
Drug Name
Torcetrapib
Synonyms
Torcetrapib [USAN]; CP 529414; CP-529414; CP-529,414; Torcetrapib (USAN/INN); Ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; Ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
Drug Type
Small molecular drug
Indication Peripheral vascular disease; Hyperlipidemia [ICD9: 272.0-272.4, 325, 430-459, 443.9; ICD10:E78, G45-G46, I60-I95, I73.9] Discontinued in Phase 2 [547324]
Company
Pfizer
Structure
Download
2D MOL

3D MOL

Formula
C26H25F9N2O4
Canonical SMILES
CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=<br />C3)C(F)(F)F)C(F)(F)F)C(=O)OC
InChI
1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
InChIKey
CMSGWTNRGKRWGS-NQIIRXRSSA-N
CAS Number
CAS 262352-17-0
PubChem Compound ID
PubChem Substance ID
ChEBI ID
ChEBI:49203
Target and Pathway
Target(s) Cholesteryl ester transfer protein Target Info Inhibitor [537463], [537492], [537579]
PANTHER Pathway CCKR signaling map ST
Reactome LDL-mediated lipid transport
HDL-mediated lipid transport
WikiPathways Statin Pathway
Lipid digestion, mobilization, and transport
References
Ref 547324Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015157)
Ref 537463The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol. 2009 Jul;24(4):364-71.
Ref 537492A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochem Pharmacol. 2009 Aug 15;78(4):315-25. Epub 2009 Mar 24.
Ref 537579Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.